Agomove is a non-steroidal anti-inflammatory agent. It has anti-inflammatory, analgesic and antipyretic properties. It is useful for the treatment of various joint disorders and acute musculoskeletal disorders.
Clinical pharmacology
Agomove ia sn anti-inflammatory, analgesic and antipyretic agent. In recommended doses, agomove produces superior therapeutic effect and is better tolerated than aspirin and indomethacin. Agomove produces its therapeutic effects by inhibiting the biosynthesis of prostaglandins also has uricosuric effect.
Piroxicam is completely absorbed from gastrointestinal tract after oral administration. Its peal concentration in plasma occurs within 2 to 4 hours. The absorption of piroxicam is not affected by the presence of food or antacids
There is enterohepatic cycling of piroxicam. The principal advantage of piroxicam is its long half-life which appears to be about 45 hours. The long half-life permits the administration of piroxicam in a single daily dose.
Indications
Agomove is a potent non-steroidal anti-inflammatory agent. It is useful for the treatment of disorders requiring anti-inflammatory and or analgesic activity, such as rheumatoid arthritis, osteo-arthritis ankylosing spondylitis, acute musculoskeletal disorders, acute gout, and degenerative joint disease
Dosage and administration
For the treatment of rheumatoid, osteo-arthritis ankylosing spondylitis e.tc the recommended starting dose of Agomove is 20mg given as single daily dose. The majority of patient respond well to 20 mg daily dose. Some patient may be maintained on 10 mg daily dose. In few patients Agomove may be required in the dose 30 mg per day given in single or divided doses.
For the management of acute gout, therapy should be initiated by single dose of 40 mg per day followed by the same dose for 5 to 7 days.
For the treatment of acute musculoskeletal diorders, Agomove be given in dose of 40 mg per day for first two days in single or divided doses. For remaining 7 to 14 days the doses should be reduced to 20 mg daily.
Contraindications
Agomove is not be used in those who have previously shown a hypersensitivity to the drug. The potential cross sensitivity to aspirin and other non-steroidal anti-inflammatory drugs. Agomove should not be given to patients in whom aspirin and other non-steroidal anti-inflammatory drugs induce the symptoms of asthma, rhinitis or urticarial.
Agomove is not be used in those patients with active peptic ulceration or a history of recurrent ulceration
Use in pregnancy and lactation
Although no teratogenic effects were seen in animal testing, the safety of piroxicam used during pregnancy or during lactation has not yet been established. Piroxicam inhibits prostaglandins synthesis. This effect, as with other non-steroidal anti-inflammatory agents has been associated with an increased incidence of dystocla and delayed parturition in pregnant animals when drug administration was continued into late pregnancy. Non-steroidal anti-inflammatory drugs are also known to induce closure of the ductus arterlosus in infants.
Use in children
Dosage recommendations and indications for use in children have not been established
Side effects
Piroxicam is generally well tolerated. Gastrointestinal symptoms are the commonly encountered side effects. Peptic ulceration and gastro-intestinal bleeding have been reported as have decreased platelet aggregation and prolonged bleeding times. Oedema and changes in liver function test have also occurred.
Skin rashes including dermal hypersensitivity has been reported. Photo allergic reactions have infrequently been associated with therapy. As with other non-steroidal anti-inflammatory drugs, Steven Johnson syndrome may develop in rare cases.
